Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH001 plus Toripalimab in advanced NSCLC and HCC
CTR20220406Phase 2Terminated
- Sponsor
- Youhe Biopharma
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of YH001, toripalimab in non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), Nonhematologic neoplasms, sponsored by Youhe Biopharma. Started Mar 2022; status: terminated.
02
Drugs
YH001toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20220406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220406.